Prescription Drug Cost Sharing
Associations With Medication and Medical Utilization and Spending and Health
Bibliographic Data
| ID | 23329347 |
|---|---|
| Authors | Dana P Goldman (0000-0001-8498-6396, RAND Corporation), Geoffrey F Joyce, Geoffrey Joyce (0000-0002-6674-0242), Yuhui Zheng |
| Year | 2007 |
| Volume | 298 |
| Issue | 1 |
| Pages | 61 |
| Publication date | 2007-07-04 |
| Peer Reviewed | Yes |
| Open Access | No |
| Type | ARTICLE |
| Venue | JAMA (JOURNAL) |
| Journal identifiers | ISSN: 0098-7484 • E-ISSN: 1538-3598 |
| Publisher | American Medical Association (AMA) (PUBLISHER) |
| DOI | 10.1001/jama.298.1.61 |
| PMID | 17609491 |
| OpenAlex | W1598242848 |
| Language | EN |
| Citations received | 53 |
| References cited | 19 |
ContextPrescription drugs are instrumental to managing and preventing chronic disease. Recent changes in US prescription drug cost sharing could affect access to them.ObjectiveTo synthesize published evidence on the associations among cost-sharing features of prescription drug benefits and use of prescription drugs, use of nonpharmaceutical services, and health outcomes.Data SourcesWe searched PubMed for studies published in English between 1985 and 2006.Study Selection and Data ExtractionAmong 923 articles found in the search, we identified 132 articles examining the associations between prescription drug plan cost-containment measures, including co-payments, tiering, or coinsurance (n = 65), pharmacy benefit caps or monthly prescription limits (n = 11), formulary restrictions (n = 41), and reference pricing (n = 16), and salient outcomes, including pharmacy utilization and spending, medical care utilization and spending, and health outcomes.ResultsIncreased cost sharing is associated with lower rates of drug treatment, worse adherence among existing users, and more frequent discontinuation of therapy. For each 10% increase in cost sharing, prescription drug spending decreases by 2% to 6%, depending on class of drug and condition of the patient. The reduction in use associated with a benefit cap, which limits either the coverage amount or the number of covered prescriptions, is consistent with other cost-sharing features. For some chronic conditions, higher cost sharing is associated with increased use of medical services, at least for patients with congestive heart failure, lipid disorders, diabetes, and schizophrenia. While low-income groups may be more sensitive to increased cost sharing, there is little evidence to support this contention.ConclusionsPharmacy benefit design represents an important public health tool for improving patient treatment and adherence. While increased cost sharing is highly correlated with reductions in pharmacy use, the long-term consequences of benefit changes on health are still uncertain.
Cost sharing · Drug · Intensive care medicine · Medical prescription · Prescription drug · Health Systems, Economic Evaluations, Quality of Life · Medication Adherence and Compliance · Medicine · Nursing · Pharmaceutical Economics and Policy · Pharmacology
The Effects of Medicare Part D on Health Outcomes of Newly Covered Medicare Beneficiaries
Take-up of Medicare Part D
Austerity
Does High-Risk Pool Coverage Meet the Needs of People at Risk for Disability
Living arrangements, chronic diseases, and prescription drug expenditures among Korean elderly
Associations Between Annual Medicare Part D Low-Income Subsidy Loss and Prescription Drug Spending and Use
Ways to Save Money in Health Care
Self-Rated Health Status Based on the Type of Health Insurance
Racial and Ethnic Disparities and Prevalence in Prescription Drug Misuse, Illicit Drug Use, and Combination of Both Behaviors in the United States
Multimorbidity and out-of-pocket expenditure on medicine in Europe
Did the Medicare Prescription Drug Program Lead to New Racial and Ethnic Disparities? Examining Long-term Changes in Prescription Drug Access among Minority Populations
Socioeconomic differences in prescription drug supplemental coverage in Canada
The impact of a co-payment increase on the consumption of type 2 antidiabetics – A nationwide interrupted time series analysis
Out of pocket or out of control
The impact of eliminating out-of-pocket payments for medicines on low-income households
Copayment policy reforms and effective care utilization by patients with persistent asthma in Taiwan
Variation in the prescription drugs covered by health systems across high-income countries
Moral Hazard in Health Insurance
Effects of Medicare Part D on Racial/Ethnic Disparities in Hospital Utilization Among Seniors
Recruiting people facing social disadvantage
Implementation of the Medicare Part D Prescription Drug Benefit is Associated with Antiretroviral Therapy Interruptions
Access to Oral Osteoporosis Drugs Among Female Medicare Part D Beneficiaries
The pharmaceutical regulation of chronic disease among the U.S. urban poor
Patient value
Centralized drug procurement and inequality
Differential own-price elasticity of demand for prescription drugs by clinical value
Out of pocket expenses
Medicaid Prescription Formulary Restrictions and Arthritis Treatment Costs
Health Insurance without Single Crossing
Keep the Single Payer Vision
Impact of a Pharmacy Copayment Increase on Medication Use in the Military Health System
Cost-related Nonadherence by Medication Type Among Medicare Part D Beneficiaries With Diabetes
Pharmacy Effect on Adherence to Antidiabetic Medications
Did Access to Ambulatory Care Moderate the Associations Between Visit Mode and Ancillary Services Utilization Across the Covid-19 Pandemic Period
Impact of Medicare Part D Plan Features on Use of Generic Drugs
Impact of a Medicaid Copayment Policy on Prescription Drug and Health Services Utilization in a Fee-for-Service Medicaid Population
Quality of Antiepileptic Treatment Among Older Medicare Beneficiaries With Epilepsy
The Effect of a Large Regional Health Plan’s Value-based Insurance Design Program on Statin Use
Hospitalizations and Deaths Among Adults With Cardiovascular Disease Who Underuse Medications Because of Cost
Unintended Consequences of a Medicaid Prescription Copayment Policy
Identifying the Prescribing Physician in US Healthcare Claims Data
Chronic Health Outcomes and Prescription Drug Copayments in Medicaid
Cancer Patients’ Trade-offs Among Efficacy, Toxicity, and Out-of-Pocket Cost in the Curative and Noncurative Setting
Continuity of Care, Medication Adherence, and Health Care Outcomes Among Patients With Newly Diagnosed Type 2 Diabetes
Patient, Physician, and Payment Predictors of Statin Adherence
Cost Control after the ACA
Porque não instituir copagamento no Sistema Único de Saúde
Understanding the patient experience of cost-related non-adherence to prescription medications through typology development and application
Policy implications of heterogeneous demand reactions to changes in cost-sharing
Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US
Patient access to health care and medicines across low-income countries
Effects of reduced cost-sharing on children's health
Patient Cost-Sharing and Healthcare Spending Growth
Adverse Events Associated With Prescription Drug Cost-Sharing Among Poor and Elderly Persons
A Copayment Increase for Prescription Drugs
The Effect of Increased Prescription Drug Cost-Sharing on Medical Care Utilization and Expenses of Elderly Health Maintenance Organization Members
Effect of Increased Cost-Sharing on Oral Hypoglycemic Use in Five Managed Care Organizations
Net Health Plan Savings From Reference Pricing for Angiotensin-Converting Enzyme Inhibitors in Elderly British Columbia Residents
Health Services Utilization With Reference Drug Pricing of Histamine2 Receptor Antagonists in British Columbia Elderly
Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical Utilization
Expanding Medicaid Drug Formulary Coverage
Effect of Tiered Prescription Copayments on the Use of Preferred Brand Medications
Ability to Pay and the Decision to Medicate
Medicare Beneficiaries??? Management of Capped Prescription Benefits
The Impact of Implementing a More Restrictive Prescription Limit on Medicaid Recipients
The Effects of an Internal Analgesic Formulary Restriction on Medicaid Drug Expenditures in Wisconsin
Differential Effect of Early or Late Implementation of Prior Authorization Policies on the Use of Cox II Inhibitors
Charging for health care
The demand for prescription drugs as a function of cost-sharing
| Unique citing works | 53 |
|---|---|
| Citations per year | 2,94 |
| Citation span | 2008 - 2026 (19) |
| Citation velocity | current |
| Highly cited | No |
| Citation types | Neutral: 53 |